Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
21
-
22
-
23
-
24
-
25
Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups.
Published 2025“…In contrast, BCVA in the non-recurrence group significantly improved from 0.31 ± 0.25 preoperatively to 0.25 ± 0.25, 0.23 ± 0.26, 0.23 ± 0.28, 0.21 ± 0.27, 0.20 ± 0.30, and 0.16 ± 0.30 over the same time points (Kruskal–Wallis test, P < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”
-
26
-
27
-
28
-
29
-
30
-
31
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…<p>(A) Ki-67 expression in parathyroid glands of rats with CKD-induced sHPT treated with Cinacalcet either early in the inactive light phase (<i>Cina1</i>; N = 10) or early in the active dark phase (<i>Cina2</i>; N = 9) compared to untreated rats with sHPT investigated at similar time points (<i>PNX1</i>; N = 7 and <i>PNX2</i>; N = 7, respective) and to normal rats investigated at similar time points (<i>ctrl1</i>; N = 9 and <i>ctrl2</i>; N = 7, respective). …”
-
32
-
33
-
34
-
35
Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae
Published 2025“…We have developed the Multiplex Integrated RPA-CRISPR/Cas12a detection Assay (MIRCA) for simultaneous detection of Neisseria gonorrheae (<i>Ng</i>) and mutations with decreased susceptibility to cephalosporins. …”
-
36
-
37
-
38
-
39
-
40